Drug Dependence, Opiate Dependence, Substance Withdrawal Syndrome
Conditions
Keywords
Opiate dependence, Benzodiazepine dependence, Polydrug Abuse, Detoxification, Withdrawal Treatment
Brief summary
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment. In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common. Objectives 1. To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ). 2. To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups. 3. To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
Interventions
DRUGBuprenorphine
DRUGValproate
Sponsors
Sorlandet Hospital HF
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
\- Polydrug dependency (at least opiate and benzodiazepine dependency)
Exclusion criteria
* No severe psychiatric illness * No history of epilepsy seizures * No pregnancy or breastfeeding * Fertile women must use contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retention in treatment | — |
| Withdrawal symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum concentration of Valproate and Buprenorphine separately and in combination | — |
| Urine testing | — |
Countries
Norway
Outcome results
None listed